Immune responses to mRNA COVID-19 vaccine in immune-deficient patients

A recent pre-print, not yet been peer-reviewed, by CITF-funded researchers Drs. Anne-Claude Gingras, Tania Watts, and Vinod Chandran of the University of Toronto, studied the antibody and T-cell responses to SARS-CoV-2 mRNA vaccines in patients with a variety of immune-mediated inflammatory diseases (IMID) who were receiving immunomodulatory maintenance therapy.